These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35051021)

  • 1. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    J Neurol; 2022 Nov; 269(11):5991-6002. PubMed ID: 35842881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study.
    Hefter H; Brauns R; Ürer B; Rosenthal D; Albrecht P
    J Neurol; 2020 May; 267(5):1340-1347. PubMed ID: 31960136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature.
    Samadzadeh S; Ürer B; Brauns R; Rosenthal D; Lee JI; Albrecht P; Hefter H
    Toxins (Basel); 2020 Aug; 12(8):. PubMed ID: 32759685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Secondary Treatment Failure during Incobotulinumtoxin-A Long-Term Treatment Demonstrated by the Drawing of Disease Severity.
    Hefter H; Brauns R; Ürer B; Rosenthal D; Albrecht P; Samadzadeh S
    Toxins (Basel); 2023 Jul; 15(7):. PubMed ID: 37505723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin.
    Hefter H; Rosenthal D; Jansen A; Brauns R; Ürer B; Bigalke H; Hartung HP; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    J Neurol; 2023 Feb; 270(2):788-796. PubMed ID: 36195775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Simpson DM; Hallett M; Ashman EJ; Comella CL; Green MW; Gronseth GS; Armstrong MJ; Gloss D; Potrebic S; Jankovic J; Karp BP; Naumann M; So YT; Yablon SA
    Neurology; 2016 May; 86(19):1818-26. PubMed ID: 27164716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
    Danchenko N; Johnston KM; Whalen J
    J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins.
    Hefter H; Hartmann CJ; Kahlen U; Samadzadeh S; Rosenthal D; Moll M
    Front Neurol; 2021; 12():636590. PubMed ID: 33633680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy.
    Walter U; Mühlenhoff C; Benecke R; Dressler D; Mix E; Alt J; Wittstock M; Dudesek A; Storch A; Kamm C
    Neurology; 2020 May; 94(20):e2109-e2120. PubMed ID: 32332130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.
    Hefter H; Spiess C; Rosenthal D
    J Neural Transm (Vienna); 2014 May; 121(5):513-9. PubMed ID: 24311063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term therapy with botulinum toxin in facial synkinesis: Retrospective data analysis of data from 1998 to 2018.
    Alipour S; Pick C; Jansen S; Rink S; Klußmann JP; Grosheva M
    Clin Otolaryngol; 2021 Jul; 46(4):758-766. PubMed ID: 33534183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US.
    Hull M; Anupindi VR; DeKoven M; He J; Bouchard J
    Adv Ther; 2023 Sep; 40(9):3986-4003. PubMed ID: 37414904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.
    Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
    Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056396
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
    Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
    Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Pseudo"-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study.
    Hefter H; Rosenthal D; Samadzadeh S
    Toxins (Basel); 2023 Oct; 15(10):. PubMed ID: 37888649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
    Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence on botulinum toxin in selected disorders.
    Zakin E; Simpson D
    Toxicon; 2018 Jun; 147():134-140. PubMed ID: 29408357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review.
    Mathevon L; Declemy A; Laffont I; Perennou D
    Ann Phys Rehabil Med; 2019 Jul; 62(4):241-251. PubMed ID: 30980953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.